Biotech · Private company · Redwood City, CA, US

Arcellx, Inc.

SEC CIK 0001786205

Track this companyFree. Adds Arcellx, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials44 recruiting or active

Pipeline programs0None found yet

Disclosed deals0None found yet

Cash runwayNot availablePrivate: no SEC financials

Clinical trials4

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaPHASE3 · ACTIVE_NOT_RECRUITING · started Aug 23, 2024ClinicalTrials.gov NCT06413498 · fetched Nov 12, 2026
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.PHASE1 · ACTIVE_NOT_RECRUITING · started Nov 28, 2022ClinicalTrials.gov NCT05457010 · fetched Nov 12, 2026
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)PHASE2 · ACTIVE_NOT_RECRUITING · started Jul 15, 2022ClinicalTrials.gov NCT05396885 · fetched Nov 12, 2026
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaPHASE1 · ACTIVE_NOT_RECRUITING · started Dec 23, 2019ClinicalTrials.gov NCT04155749 · fetched Nov 12, 2026